继Arrowhead的INHBE、ALK7 siRNA管线在减重减脂领域实现概念性验证后，小核酸可以在慢病领域重做一遍的扩张逻辑愈发顺畅，现在被攻陷的有心血管、减重代谢，下一个是什么呢？ 肾科大概率是2026年下一个大爆点。 为何有如此判断？再生元每4周注射一次的靶向C5补体Cemdisiran将在2026年递交治疗全身重症肌无力（gME）的BLA，在成为首个C5补体的小核酸药物的同时，在gME展现的疗效和安全性有望延展至IgA肾病和阵发性睡眠性血红蛋白尿（PNH）；其次，2026年上半年Ionis/罗氏的CFB ASO管线Sefaxersen有望读出IgA肾病的三期数据，冲击肾病的第一个小核酸重磅炸弹。 要知道，舶望制药和诺华的合作管线适应症涵盖重度高甘油三酯血症(sHTG)和混合型血脂异常，以及涉及ANGPTL3靶点管线，而圣因生物和礼来的合作同样关乎ANGPTL3靶点，这些适应症和靶点均经过Ionis、Arrowhead和Alnylam管线概念验证，赛道强验证催化了几项巨额的BD。 同样，无论是C5还是CFB均为关键补体因子，补体小核酸赛道数据强验证同样大概率会催化一些重磅交易。

Partnership enables Evry Health to provide its members with cancer screening, treatment and survivorship care through Color's clinical-first, oncologist-led service BURLINGAME, Calif., Jan. 7, 2026 /PRNewswire/ -- Color Health today announced a partnership with insurer Evry Health to strengthen employer health plans with Color's clinical-first, oncologist-led cancer care service. With this collaboration, Evry Health members will receive access to a full continuum of oncologist-led cancer care, i

HAIFA, Israel, Jan. 7, 2026 /PRNewswire/ -- Remedy Cell, a clinical-stage biopharmaceutical company focused on the development of proprietary cell-derived therapies for fibrotic diseases, today announces the initiation of "a partially-blinded randomized Phase 1b single and repeat dose (4-cohort) safety & tolerability study of RC-0315/Placebo administered intra-bronchially to idiopathic pulmonary fibrosis patients." The primary objective of the RC-0315 First-in-Human, Phase 1b clinical study is t

IRVINE, Calif., Jan. 7, 2026 /PRNewswire/ -- Spiro Medical, Inc., a Newco established to develop the first of its kind Pulmonary Neuromodulation System (PNM) for the treatment of Asthma announced today the closing of a $67 million Series A equity financing. The financing included a syndicate of venture investors led by Andera Partners (Paris), Omega Funds (Geneva/Boston) and Sherpa Healthcare Partners (Cayman Islands) and joined by HSG (Hong Kong), Supernova Invest (Paris), Northern Light Ventu

WASHINGTON, Jan. 7, 2026 /PRNewswire/ -- Today, clinicians from top medical institutions announced the launch of the Alzheimer's Policy Working Group, a voluntary, interdisciplinary organization composed of frontline medical leaders in specialty and primary care who are advancing practical reforms to improve early diagnosis and care for Alzheimer's patients. In its inaugural report, the working group outlines timely, actionable recommendations that will empower primary care providers to strength

Recognizing exceptional leadership in patient education and clinical skill in the GammaTile procedure TEMPE, Ariz., Jan. 7, 2026 /PRNewswire/ -- GT Medical Technologies, a medical device company dedicated to improving the lives of patients with brain tumors, today announced UNC Health as the latest GammaTile® Center of Excellence Program designation. The program recognizes leaders in patient care dedicated to advancing brain tumor treatment. Physicians and their institutions who receive this des

BOSTON and HOUSTON, Jan. 7, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration that unites SOPHiA GENETICS' AI-powered analytics with MD Anderson's clinical and scientific expertise to accelerate data-driven cancer care through new tools that can accurately analyze, interpret and translate diagnostic results into clinical practice. As part of the coll

Recordati Joins Boehringer Ingelheim Venture Fund in Financing Round, with Participation from Delos and Blue Bay Capital New Investment, Combined with Recent $8.4 Million ARPA-H Award, Brings Funds Raised for Seed Round as of Q4 2025 to $16.4 Million CAMBRIDGE, Mass., Jan. 7, 2026 /PRNewswire/ -- STRM.BIO, a biotechnology company pioneering non-viral delivery technologies for in vivo cell and gene therapy, today announced $8 million in Series Seed 2 financing. The financing provided by Recordati

科学家创业融资的技巧和坑（科学家创业必看，一不留神让你卖房子卖车还债，并成为银行失信人员） 【计算材料学】2023年高浏览量文章精选 来自公众号：小柯化学 本文以传播知识为目的，如有侵权请后台联系我们，我们将在第一时间删除。 2026年1月5日，厦门大学化学化工学院/表界面化学全国重点实验室霍浩华教授团队在Nature Chemistry期刊上发表题为“Direct enantioselective C(sp3)–H coupling of N-alkyl anilines via metallaphotoredox catalysis”的研究成果。 该成果报道了一个通用的金属-光催化C(sp3)–H键不对称偶联平台。该体系开发了一个结构简单的大位阻二芳基酮新光催化剂，结合手性镍催化剂，高对映选择性地实现了多种N-烷基苯胺与不同（杂）芳基卤化物的偶联，为药物研发中高效构建手性α-芳基胺类分子提供了新途径。 论文通讯作者为霍浩华教授；第一作者为祖维赛博士。 胺类结构，尤其是N-烷基苯胺，是药物、农药及天然产物中不可或缺的核心骨架。在药物开发中，直接在其三维骨架上进行α-C(sp3)-H键

☝ 点击上方 一键预约 ☝   最新最热的医药健康新闻政策 ☝ ☝ 点击查看峰会活动议程 ☝ ☝  近期，国家医疗保障局医药价格和招标采购指导中心对今年前三季度零售端累计销售额排名靠前的药品进行了梳理，形成清单供各地参考。此类药品群众常在药店，网络平台购买使用，对零售端药价和挂网价的差异敏感，也是监测异常高价的重点。请各地以这些药品零售端价格作为锚点，与省级采购平台挂网价做好比对。平台挂网价格明显高于定点药店或网络及时达价格的，请参照定点医疗机构协议有关"不得实行不公平，歧视性高价"等规定主动提示和治理；定点药店价格明显高于平台挂网价格的，要根据定点药店协议管理要求，分析研判合理性，排查风险；明显有悖常理而不自主纠正的，要及时提示行政部门采取适当措施。 2025年前三季度零售端销售额排名靠前的药品清单 有需要《22025年前三季度零售端销售额排名靠前的药品清单》（完整Excel版），请扫描下方二维码添加客服微信咨询，申请加入药闻康策高端会员群获取。 药闻康策 新媒体矩阵微信公众号 点击下方  一键关注 【免责声明】 1.“药闻康策”部分文章信息来源于网络转载是出于传递更多信息之目的，并